ZW-171 is under clinical development by Zymeworks and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 74% phase transition ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Although life-threatening and incurable, mesothelioma is not always fatal. Many patients have become long-term survivors.

The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological ...

Purpose The etiology, diagnosis, staging, and management of malignant pleural mesothelioma (MPM) are reviewed, with an emphasis on clinical trials of newer approaches to first-line, second-line ...

short cricket captions Breakthrough in the treatment of malignant pleural mesothelioma: Bristol-Myers Squibb's "O+Y" combination approved by FDA Today, five new class 1 drugs were approved for ...

This study aims to generate a critical account of the experiences of presentation, diagnosis, treatment and care for current and former school-based education workers with mesothelioma. At present, ...